Author:
Nimal Snehal,Kumbhar Navanath,Saruchi ,Rathore Shriya,Naik Nitin,Paymal Sneha,Gacche Rajesh N.
Abstract
AbstractTriple-negative breast cancer (TNBC) is a metastatic disease and a formidable treatment challenge as it does not respond to existing therapies. Epigenetic regulators play a crucial role in the progression and metastasis by modulating the expression of anti-apoptotic, pro-apoptotic markers and related miRNAs in TNBC cells. We have investigated the anti-TNBC potential of dietary flavonoid ‘Apigenin’ and its combination with Vorinostat on MDA-MB-231 cells. At Apigenin generated ROS, inhibited cell migration, arrested the cell cycle at subG0/G1 phases, and induced apoptotic-mediated cell death. Apigenin reduced the expression of the class-I HDACs at the transcriptomic and proteomic levels. In the immunoblotting study, Apigenin has upregulated pro-apoptotic markers and downregulated anti-apoptotic proteins. Apigenin inhibited the enzymatic activity of HDAC/DNMT and increased HAT activity. Apigenin has manifested its effect on miRNA expression by upregulating the tumor-suppressor miR-200b and downregulation oncomiR-21. Combination study reduced the growth of TNBC cells synergistically by modulating the expression of epigenetic and apoptotic regulators. Molecular docking and MD simulations explored the mechanism of catalytic inhibition of HDAC1 and HDAC3 and supported the in-vitro studies. The overall studies demonstrated an anti-TNBC potential of Apigenin and may help to design an effective strategy to treat metastatic phenotype of TNBC.
Publisher
Springer Science and Business Media LLC
Reference130 articles.
1. https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
2. https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/triple-negative.html.
3. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249. https://doi.org/10.3322/caac.21660 (2021) (Epub 2021 Feb 4).
4. Derakhshan, F. & Reis-Filho, J. S. Pathogenesis of triple-negative breast cancer. Annu. Rev. Pathol. 24(17), 181–204. https://doi.org/10.1146/annurev-pathol-042420-093238 (2022).
5. Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19(2), 91–113. https://doi.org/10.1038/s41571-021-00565-2 (2022) (Epub 2021 Nov 9).